Trial Profile
Phase III trial of a 3-month injectable formulation of sustained-release leuprorelin for prostate cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2014
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 10 Feb 2014 New trial record